Investors

Corporate News & Publications

CLINUVEL's company releases, including archives.

Friday, 24 February 2017 19:44

Appendix 4D and Half Year Report

Thursday, 16 February 2017 00:41

CLINUVEL Newsletter - February 2017

Tuesday, 31 January 2017 19:34

Appendix 4C - Quarterly report

Friday, 23 December 2016 20:08

Appendix 3Y

Tuesday, 20 December 2016 22:03

CLINUVEL Newsletter - December 2016

Tuesday, 13 December 2016 02:25

Appendix 3Y

Monday, 28 November 2016 15:01

Results of Meeting

Sunday, 27 November 2016 13:19

Managing Director's AGM Presentation

Melbourne, Australia and New York, US, 9 November 2016 CLINUVEL [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today announced that it met on 7 November with the US Food and Drug Administration’s (FDA’s) Division of Dermatology and Dental Products (DDDP) to discuss the content and format of a new drug application (NDA) submission as part of the US regulatory pathway for CLINUVEL’s medicinal product SCENESSE® (afamelanotide 16mg). The pharmaceutical product has been developed for the treatment of erythropoietic protoporphyria (EPP)1, a rare genetic enzymatic disorder causing lifelong absolute light intolerance. The pre-NDA meeting allowed both parties to discuss…
Page 1 of 53

Quick Links